VaxigripTetra

Ingredient

A/Victoria/2570/2019 (H1N1)pdm09 – like strain (A/Victoria/2570/2019, IVR-215)
A/Hong Kong/2671/2019 (H3N2) – like strain (A/Hong Kong/2671/2019, IVR-208)
B/Washington/02/2019 – like strain (B/Washington/02/2019, wild type)
B/Phuket/3073/2013 – like strain (B/Phuket/3073/2013, wild type)

Content

Indication

the prevention of influenza disease caused by the two influenza A virus
subtypes and the two influenza B virus types contained in the vaccine for:
– active immunisation of adults, including pregnant women, and children from 6 months of age.
– passive protection of infants less than 6 months of age and born to women vaccinated during
pregnancy

Viviant

Ingredient

bazedoxifene acetate

Content

bazedoxifene acetate(as bazedoxifene) 20mg

Indication

Treatment and prevention of osteoporosis in postmenopausal women.

**However, this drug reduced the incidence of spinal fractures, but the effectiveness for non-spinal fractures has not been established.

Vyxeos liposomal inj.

Ingredient

Each vial contains 44 mg of daunorubicin and 100 mg of cytarabine

Content

Powder for concentrate for solution for infusion.
Purple, lyophilised cake.

Indication

Vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute
myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)